These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24915189)

  • 1. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
    Yea SS; So L; Mallya S; Lee J; Rajasekaran K; Malarkannan S; Fruman DA
    PLoS One; 2014; 9(6):e99486. PubMed ID: 24915189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
    Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
    Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
    So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
    J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
    J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinases p110α and p110β have differential roles in insulin-like growth factor-1-mediated Akt phosphorylation and platelet priming.
    Blair TA; Moore SF; Williams CM; Poole AW; Vanhaesebroeck B; Hers I
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1681-8. PubMed ID: 24903091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.
    Rabot M; El Costa H; Polgar B; Marie-Cardine A; Aguerre-Girr M; Barakonyi A; Valitutti S; Bensussan A; Le Bouteiller P
    Int Immunol; 2007 Apr; 19(4):401-9. PubMed ID: 17307798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
    Wang X; Li JP; Yang Y; Ding J; Meng LH
    Acta Pharmacol Sin; 2013 Sep; 34(9):1201-7. PubMed ID: 23892273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
    Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syk regulation of phosphoinositide 3-kinase-dependent NK cell function.
    Jiang K; Zhong B; Gilvary DL; Corliss BC; Vivier E; Hong-Geller E; Wei S; Djeu JY
    J Immunol; 2002 Apr; 168(7):3155-64. PubMed ID: 11907067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
    Kondadasula SV; Roda JM; Parihar R; Yu J; Lehman A; Caligiuri MA; Tridandapani S; Burry RW; Carson WE
    Blood; 2008 Apr; 111(8):4173-83. PubMed ID: 18174382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Active Compounds Targeting Human Natural Killer Cell Activation Identifying Daphnetin as an Enhancer for IFN-γ Production and Direct Cytotoxicity.
    Yao B; Yang Q; Yang Y; Li Y; Peng H; Wu S; Wang L; Zhang S; Huang M; Wang E; Xiong P; Luo T; Li L; Jia S; Deng Y; Deng Y
    Front Immunol; 2021; 12():680611. PubMed ID: 34956168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
    Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
    Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K p85 β regulatory subunit deficiency does not affect NK cell differentiation and increases NKG2D-mediated activation.
    Rojas JM; Spada R; Sanz-Ortega L; Morillas L; Mejías R; Mulens-Arias V; Pérez-Yagüe S; Barber DF
    J Leukoc Biol; 2016 Dec; 100(6):1285-1296. PubMed ID: 27381007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
    Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.
    Höland K; Boller D; Hagel C; Dolski S; Treszl A; Pardo OE; Cwiek P; Salm F; Leni Z; Shepherd PR; Styp-Rekowska B; Djonov V; von Bueren AO; Frei K; Arcaro A
    PLoS One; 2014; 9(4):e94132. PubMed ID: 24718026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.
    Bommarito D; Martin A; Forcade E; Nastke MD; Ritz J; Bellucci R
    Cancer Immunol Immunother; 2016 Mar; 65(3):355-66. PubMed ID: 26883876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation.
    Guo H; Samarakoon A; Vanhaesebroeck B; Malarkannan S
    J Exp Med; 2008 Sep; 205(10):2419-35. PubMed ID: 18809712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.
    Soler A; Figueiredo AM; Castel P; Martin L; Monelli E; Angulo-Urarte A; Milà-Guasch M; Viñals F; Baselga J; Casanovas O; Graupera M
    Clin Cancer Res; 2016 Dec; 22(23):5805-5817. PubMed ID: 27225693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
    Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
    J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.